StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) operating KPIs

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)

Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%

Gilead Sciences strategic Oncology Affiliate — Arcus Biosciences (NYSE: RCUS) Total Revenues ($M) ($M)

Arcus Biosciences, Inc. (NYSE: RCUS, CIK 0001724521) Form 10-Q / 10-K

QuarterlyAnnual
Latest, Q2 2026
33
Period ended Jun 30, 2026
Change on a year earlier
+312.5%
8 in Q2 2025
History
30 quarters
Since Q1 2019
Sources
18
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedStrategic Oncology Affiliate — Arcus Biosciences (NYSE: RCUS) Total Revenues ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202633+312.5%Arcus Biosciences (RCUS) Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 20267-12.5%Arcus Biosciences (RCUS) Form 10-Q (filed 2026-05-05) ↗
Q4 2025Dec 31, 202511-52.2%Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗
Q3 2025Sep 30, 20256-14.3%Arcus Biosciences (RCUS) Form 10-Q (filed 2025-10-28) ↗
Q2 2025Jun 30, 20258-27.3%Arcus Biosciences (RCUS) Form 10-Q (filed 2026-08-05) ↗
Q1 2025Mar 31, 20258-20.0%Arcus Biosciences (RCUS) Form 10-Q (filed 2026-05-05) ↗
Q4 2024Dec 31, 202423-146.9%Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗
Q3 2024Sep 30, 20247-78.1%Arcus Biosciences (RCUS) Form 10-Q (filed 2025-10-28) ↗
Q2 2024Jun 30, 202411-62.1%Arcus Biosciences (RCUS) Form 10-Q (filed 2025-08-06) ↗
Q1 2024Mar 31, 202410-60.0%Arcus Biosciences (RCUS) Form 10-Q (filed 2025-05-06) ↗
Q4 2023Dec 31, 2023-49+22.5%Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗
Q3 2023Sep 30, 202332-3.0%Arcus Biosciences (RCUS) Form 10-Q (filed 2024-11-06) ↗
Q2 2023Jun 30, 202329+7.4%Arcus Biosciences (RCUS) Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 202325+38.9%Arcus Biosciences (RCUS) Form 10-Q (filed 2024-05-08) ↗
Q4 2022Dec 31, 2022-40-111.3%Arcus Biosciences (RCUS) Form 10-K (filed 2025-02-25) ↗
Q3 2022Sep 30, 202233+247.4%SEC Filing ↗

Breakdown

What makes up strategic oncology affiliate — arcus biosciences (nyse: rcus) total revenues ($m)

Cite this data

StockData. (2026). Gilead Sciences Strategic Oncology Affiliate — Arcus Biosciences (NYSE: RCUS) Total Revenues ($M) ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rcus_rev_tot

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.